Volume 105, Issue 3 pp. 795-798

Syngeneic stem cell transplantation for HIV-related lymphoma

P. Campbell

P. Campbell

Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia

Search for more papers by this author
H. Iland

H. Iland

Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia

Search for more papers by this author
J. Gibson

J. Gibson

Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia

Search for more papers by this author
D. Joshua

D. Joshua

Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia

Search for more papers by this author
First published: 25 December 2001
Citations: 30
Dr H. J. Iland, The Kanematsu Laboratories, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. e-mail: [email protected]

Abstract

The treatment of human immunodeficiency virus (HIV)-related lymphoma is beset by a number of therapeutic limitations. High-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) for relapsed disease is one option, but may be compromised by unacceptable treatment-related morbidity and mortality. We describe an HIV-positive male with relapsed immunoblastic non-Hodgkin's lymphoma (NHL) who successfully received salvage chemotherapy followed by a syngeneic PBSCT from his HIV-negative (hepatitis C positive) brother. At 15 months post-transplant he remains in complete remission with low-level HIV viral load, an improved CD4 lymphocyte count and absent anti-hepatitis C antibodies. We believe selected patients with relapsed HIV-related NHL should be considered for high-dose therapy.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.